PharmaBlock Sciences Nanjing Inc
SZSE:300725

Watchlist Manager
PharmaBlock Sciences Nanjing Inc Logo
PharmaBlock Sciences Nanjing Inc
SZSE:300725
Watchlist
Price: 34.39 CNY -5.39% Market Closed
Market Cap: 6.8B CNY
Have any thoughts about
PharmaBlock Sciences Nanjing Inc?
Write Note

PharmaBlock Sciences Nanjing Inc
Accounts Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

PharmaBlock Sciences Nanjing Inc
Accounts Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
PharmaBlock Sciences Nanjing Inc
SZSE:300725
Accounts Receivables
ÂĄ399.7m
CAGR 3-Years
43%
CAGR 5-Years
40%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Accounts Receivables
ÂĄ3.2B
CAGR 3-Years
5%
CAGR 5-Years
15%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Accounts Receivables
ÂĄ809.6m
CAGR 3-Years
9%
CAGR 5-Years
9%
CAGR 10-Years
14%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Accounts Receivables
ÂĄ6.2B
CAGR 3-Years
0%
CAGR 5-Years
3%
CAGR 10-Years
14%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Accounts Receivables
ÂĄ10.1B
CAGR 3-Years
21%
CAGR 5-Years
36%
CAGR 10-Years
28%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Accounts Receivables
ÂĄ98.4m
CAGR 3-Years
-16%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

PharmaBlock Sciences Nanjing Inc
Glance View

Market Cap
6.8B CNY
Industry
Pharmaceuticals

PharmaBlock Sciences (Nanjing), Inc. engages in the innovation of chemistry products and services throughout the pharmaceutical research and development process. The company is headquartered in Nanjing, Jiangsu and currently employs 1,735 full-time employees. The company went IPO on 2017-11-10. The firm's primary products include aromatic heterocyclic drug molecular building blocks, common saturated alicyclic drug molecular building blocks, four-membered ring drug molecular building blocks and special saturated ring drug molecular building blocks. The firm is also involved in development, production and sales of pharmaceutical intermediates, and provides technical services related to the development and process production of pharmaceutical molecular building blocks.

Intrinsic Value
54.46 CNY
Undervaluation 37%
Intrinsic Value
Price

See Also

What is PharmaBlock Sciences Nanjing Inc's Accounts Receivables?
Accounts Receivables
399.7m CNY

Based on the financial report for Sep 30, 2024, PharmaBlock Sciences Nanjing Inc's Accounts Receivables amounts to 399.7m CNY.

What is PharmaBlock Sciences Nanjing Inc's Accounts Receivables growth rate?
Accounts Receivables CAGR 5Y
40%

Over the last year, the Accounts Receivables growth was -11%. The average annual Accounts Receivables growth rates for PharmaBlock Sciences Nanjing Inc have been 43% over the past three years , 40% over the past five years .

Back to Top